Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Ridgeback Capital

Investor type Family Investment Office
Founders Wayne Holman

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 28
Average round size
info
The average size of a deal this fund participated in
$88M
Portfolio companies 25
Rounds per year 1.75
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 11
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Biopharma
  • Pharmaceutical
Summary

The main office of represented VC is situated in the New York. The company was established in North America in United States.

We also calculated 1 valuable employee in our database.

Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Adaptimmune, 4D Molecular Therapeutics, Stem Cell Therapeutics. We can highlight the next thriving fund investment areas, such as Industrial, Health Care. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The real fund results show that this VC is 2 percentage points more often commits exit comparing to other companies. Deals in the range of 50 - 100 millions dollars are the general things for fund. The increased amount of exits for fund were in 2019. The high activity for fund was in 2018. The fund is constantly included in less than 2 investment rounds annually. Opposing the other organizations, this Ridgeback Capital works on 60 percentage points more the average amount of lead investments.

The usual cause for the fund is to invest in rounds with 9-10 partakers. Despite the Ridgeback Capital, startups are often financed by Polaris Partners, UBS Asset Management, Remeditex Ventures. The meaningful sponsors for the fund in investment in the same round are venBio Partners, OrbiMed, F-Prime Capital. In the next rounds fund is usually obtained by Eight Roads Ventures, Cancer Prevention and Research Institute of Texas.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Addisco Value Partner Fund Charlotte, North Carolina, United States
Alphemy Capital fund -
ALPS Information Technology Fund Auburn Hills, Michigan, United States
Beijing Tianze Investment Management Beijing, Beijing, China
Brii Biosciences California, San Francisco, United States
China Merchants Venture China, Guangdong, Shenzhen
Kassabov Santos Ventures, LLC Florida, United States, Winter Park
Lanua Asia fund -
Link Hui Capital -
Malaysian Technology Development Corporation Kuala Lumpur, Malaysia
Mayfair Equity Partners England, London, United Kingdom
Nordnet Bank AB Copenhagen, Denmark, Hovedstaden
Propel(X) California, San Francisco, United States
Pure Imagination Brands California, Santa Monica, United States
Rally Capital -
Wolfson Equities New York, New York, United States
Xpring California, San Francisco, United States
Zhaoren Touzi China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Crisp

Food and Beverage
SaaS
Software
$35M02 Feb 2022 New York, New York, United States

Freenome

Biotechnology
Health Care
Health Diagnostics
Personal Health
$300M07 Dec 2021 South San Francisco, California, United States

Quell Therapeutics

Association
Biotechnology
Education
$156M29 Nov 2021 London, England, United Kingdom

Arbor Biotechnologies

Biopharma
Biotechnology
Life Science
$215M09 Nov 2021 Cambridge, Massachusetts, United States

Garuda Therapeutics

Biotechnology
Life Science
Therapeutics
$72M23 Sep 2021 Natick, Massachusetts, United States

Turnstone Biologics

Biotechnology
Innovation Management
Therapeutics
$80M14 Jul 2021 San Francisco, California, United States

TwinStrand Biosciences

Biotechnology
Genetics
Health Care
$50M06 May 2021 Seattle, Washington, United States

Pyxis Oncology

Biotechnology
Health Care
Pharmaceutical
$152M30 Mar 2021 Boston, Massachusetts, United States

Acepodia

Biotechnology
Health Care
Therapeutics
$47M16 Mar 2021 Vallejo, California, United States
News
Pyxis Oncology Raises $152M Series B Round

– Pyxis Oncology from Longwood Fund has closed a $152m Series B financing.
– The round was led by Arix Bioscience and co-led by RTW Investments, LP.
– New investors included Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management LLC, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital (a Citadel company), Laurion Capital Management, Logos Capital and LifeSci Venture Partners.

Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline

– Caribou Biosciences, Inc. announced the successful completion of an oversubscribed $115m Series C financing.
– Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.
– The Series C financing was co-led by new premier healthcare investors Farallon Capital Management, PFM Health Sciences, and Ridgeback Capital Investments.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Ridgeback Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: